MARKET WIREYahoo! Finance Canada • 22h ago
IQVIA Holdings Inc. (IQV) Stock Price, News, Quote & HistoryYahoo! Finance Canada report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
Why IQV Stock dropped -3.32% Today — RQD Quant Desk Flash
$258.44 -3.32% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $256.40
IQVIA Holdings Inc. (IQV) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $44.06B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IQV Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IQV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, IQVIA Holdings Inc. (NYSE: IQV) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $258.44 (-3.32% 1D, market cap $44.06B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IQV ranks #154 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IQV compare to INCY and MEDP in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), IQV carries a Roarable C- (61/100 RQD), trailing P/E of 33.3x, gross margin of —, and ROIC of 9.4%. By comparison, INCY (Incyte Corp.) holds a A grade (88/100 RQD, P/E 18.4x, ROIC 42.4%, cap $24.54B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (77/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.24B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IQV?
▼
Per IQV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478242), IQVIA Holdings Inc. generated $16.31B in revenue (+5.9% YoY), $1.36B in net income, and $1.92B in free cash flow against $29.94B in total assets and $13.88B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $256.40 (-0.79%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 11.8% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C+ · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE+1.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IQV)Realized 20D OHLCV Swing Band: ±6.9%
Deterministic 5-Pillar Attribution (61/100 Composite)
🔍 WHY IQV SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (25% of score)
20D Institutional Volume Accumulation (±6.9% realized swing band)
▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 11.8% FCF Margin ($1.92B FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)
Macro rate sensitivity & RSI-14 (48.3) create a -10 pt regime headwind
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$262.01+5.6% Next Q
69
Q2 (-2Q)Grade B-$276.63+0.9% Next Q
66
Q3 (-1Q)Grade C+$279.04-7.4% Next Q
64
CurrentGrade C-$258.44+0.5% Hist 90D α
61
Trajectory: B- (69) → C- (61)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the IQV Bull Thesis Could Fail
Even with a 61/100 (C-) score, IQV faces multiple-compression risk if 33.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($266.85) or 200D SMA ($210.04) invalidates the momentum regime and cuts Target Base ($261.93) toward Bear Floor ($204.31).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IQV• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IQV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IQV Stock dropped -3.32% Today — RQD Quant Desk Flash
IQVIA Holdings Inc. (IQV) dropped -3.32% to $258.44, trading at 80% of its 52-week range ($154.5 – $284.5). Solid steady margins (9% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 80% of its 52-week range ($154.5 – $284.5) with RSI-14 at 48.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.9% around $258.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 52% gross margin and $1.9B annual free cash flow.
Live IQV Headlines & Catalysts
MARKET WIREChartMill • 1d ago
IQVIA HOLDINGS INC (NYSE:IQV) Sets Up for Breakout With Strong Technical RatingsChartMill report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREmarketscreener.com • 1d ago
Iqvia Holdings Inc. Stock (IQV) - Quote NYSEmarketscreener.com report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStockInvest.us • 1d ago
Iqvia Holdings Stock Price Forecast. Should You Buy IQV?StockInvest.us report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeeking Alpha • 1d ago
IQVIA gains as R&D Solutions drive Q3 beatSeeking Alpha report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
IQVIA Holdings Inc (IQV) Stock Up 3.5% but GF Value Says OvervalGuruFocus report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?Yahoo Finance report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
IQVIA (IQV) Stock Could Be Undervalued Following Its 55% RunSimply Wall St report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 3d ago
IQV Q3 deep dive: AI adoption and clinical momentum drive growth, guidance raisedClinical research company IQVIA (NYSE: IQV) reported Q3 2026 results topping the market’s revenue expectations, with sales up 8% year on year to $4.43 billion. The company expects the full year’s revenue to be around $17
CATALYSTYahoo • 3d ago
5 revealing analyst questions from IQVIA’s Q3 earnings callIQVIA delivered an 8% year-over-year revenue increase in Q3, with results that outpaced Wall Street expectations and prompted a positive market reaction. Management attributed this performance to accelerated growth in bo
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (IQV Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IQV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +60.58%▼ SUPPORT BREAKDOWN
2026-11-03O $275.1H $275.1L $258.4C $258.4VOL 1.15M
RES: $334.5SUP: $271.5SMA50: $266.9SMA200: $210.0
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IQV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
25.7%/yr Implied 5Y Growth
vs. +5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on IQV today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IQV. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IQV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IQV)
Health Care Rank #154 of 1015
⚔️ INCY vs IQV Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IQV vs. INCY, MEDP, CRL, ICLR)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, IQVIA Holdings Inc. (IQV) ranks #154 by composite RQD confidence (61/100, grade C-) and #41 by equity capitalization ($44.06B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 88/100 (A) compared with IQV at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IQV
ACTIVE
IQVIA Holdings Inc. | C- | 61/100 | 33.3x | — | 9.4% | -3.32% | $44.06B | Benchmark Subject |
| INCY Incyte Corp. | A | 88/100 | 18.4x | 92.8% | 42.4% | -0.29% | $24.54B | /incy-vs-iqv → |
| MEDP Medpace Holdings Inc. | B+ | 77/100 | 42.0x | — | 27.9% | -0.59% | $18.24B | /medp-vs-iqv → |
| CRL Charles River Laboratories International Inc. | C | 64/100 | — | — | 0.4% | -5.81% | $17.16B | /crl-vs-iqv → |
| ICLR ICON plc | B | 72/100 | 71.9x | — | 3.1% | -2.94% | $16.18B | /iclr-vs-iqv → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001478242 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), IQVIA Holdings Inc. (IQV) reported GAAP revenue of $16.31B (+5.9% vs. FY2024 revenue of $15.40B , and +8.8% cumulative change since FY2023) , GAAP net income of $1.36B, operating cash flow of $2.65B, and free cash flow of $1.92B (-5.1% YoY). On the balance sheet, IQV closed FY2025 with $29.94B in total assets against $13.88B in total debt (Altman Z-Score: 2.22, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $16.31B | $1.36B | $2.65B | $1.92B | $29.94B | $13.88B |
| FY2024 (FY) | 2024-12-31 | $15.40B | $1.37B | $2.72B | $2.02B | $26.90B | $12.84B |
| FY2023 (FY) | 2023-12-31 | $14.98B | $1.36B | $2.15B | $1.47B | $24.93B | $5.83B |
3. IQV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IQV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, IQVIA Holdings Inc. (NYSE: IQV) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $258.44 (-3.32% 1D, market cap $44.06B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IQV ranks #154 in composite RQD confidence.
How does IQV compare to INCY and MEDP in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), IQV carries a Roarable C- (61/100 RQD), trailing P/E of 33.3x, gross margin of —, and ROIC of 9.4%. By comparison, INCY (Incyte Corp.) holds a A grade (88/100 RQD, P/E 18.4x, ROIC 42.4%, cap $24.54B) and MEDP (Medpace Holdings Inc.) posts a B+ grade (77/100 RQD, P/E 42.0x, ROIC 27.9%, cap $18.24B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IQV?
Per IQV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478242), IQVIA Holdings Inc. generated $16.31B in revenue (+5.9% YoY), $1.36B in net income, and $1.92B in free cash flow against $29.94B in total assets and $13.88B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IQV trading relative to its 50-day, 200-day, and 52-week technical levels?
IQV last traded at $258.44 (-3.32% on volume of 1,369,121 shares), positioning the stock -3.15% below its 50-day simple moving average ($266.85) and +23.04% above its 200-day simple moving average ($210.04). Across its 52-week range of $154.50 to $284.50, IQV sits at the 80.0% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.9% ($240.61 to $276.27).
ROARABLE RATING BRIEF • RQD 61/100 (C-)
✓ SEC XBRL & RQD VERIFIED
IQV — IQVIA Holdings Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
IQVIA Holdings Inc. (IQV) earns a live Roarable RQD composite score of 61/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $258.44 (-3.32% 1D, market capitalization $44.06B).
- Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 9.4%, gross margin of —, operating margin of 13.4%, and free cash flow yield of 4.24%.
- Whale 13F & Options Flow (15/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.16x equity beta, Altman Z-Score of 2.22, Piotroski F-Score of 6/9, and Debt/Equity of 2.14x.
2. Business Model, Unit Margins & SEC Financial Trajectory
IQVIA Holdings Inc. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Commercial Physical & Biological Resarch industry..3B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), IQVIA Holdings Inc. (IQV) reported $16.31B in annual revenue (up from $15.40B in FY2024, +5.9% YoY) and $1.36B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($14.98B revenue, $1.36B net income) through FY2025, IQV scaled operating cash flow to $2.65B and free cash flow to $1.92B, backed by $29.94B in total assets against $13.88B in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C- • RQD 61/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 4.24% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $154.50 – $284.50 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 33.3x trailing P/E and 20.4x EV/EBITDA against 13.4% operating margins and a 1.16x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
— for upstream or downstream dependencies, sector correlations, or second-order bottlenecks beyond the stated sector (Health Care) and industry classification.
- Key Question #1: Can IQV sustain or expand its 13.4% operating margin and 9.4% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $16.31B and free cash flow of $1.92B, how will capital allocation balance growth reinvestment against $13.88B in total debt?
- Key Question #3: How sensitive is IQV's 31.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.16x)?
IQV Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for IQVIA Holdings Inc. (IQV) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo! Finance Canada • 22h ago
IQVIA Holdings Inc. (IQV) Stock Price, News, Quote & History Yahoo! Finance Canada report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ChartMill • 1d ago
IQVIA HOLDINGS INC (NYSE:IQV) Sets Up for Breakout With Strong Technical Ratings ChartMill report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE marketscreener.com • 1d ago
Iqvia Holdings Inc. Stock (IQV) - Quote NYSE marketscreener.com report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 1d ago
Iqvia Holdings Stock Price Forecast. Should You Buy IQV? StockInvest.us report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Seeking Alpha • 1d ago
IQVIA gains as R&D Solutions drive Q3 beat Seeking Alpha report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
IQVIA Holdings Inc (IQV) Stock Up 3.5% but GF Value Says Overval GuruFocus report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy? Yahoo Finance report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
IQVIA (IQV) Stock Could Be Undervalued Following Its 55% Run Simply Wall St report covering IQVIA Holdings Inc. (IQV) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IQV Bull vs. Bear Conversation Board — What's Your Call at $258.44?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IQV 🐻 33% BEARISH CONVICTION
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH
🎯 Target: $350.20 (+31.0%)
📌 Pinned Debate Institutional accumulation and options positioning earn the top RQD pillar score of 18 of 20, while a GREEN-flagged catalyst cites a Q3
Don't sleep on IQV's setup in Health Care. Institutional accumulation and options positioning earn the top RQD pillar score of 18 of 20, while a GREEN-flagged catalyst cites a Q3 beat driven by R&D Solutions.. Beta of 1.16 means it moves fast when momentum turns, and the 5-pillar RQD gauge (61/100) backs up the fundamental quality.
EarningsSniper 🐂 BULL
Both sides have a point here — IQV's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $205.84 (-23.0%)
Spot @ $267.33 Debt/Equity of 2.14 and reported debt rising from $5.83B to $13.88B, with a Forensic Balance Sheet score of 10 of 20 and a P/E TTM
I respect the product at IQVIA Holdings Inc., but the stock at $267.33 is a different story. Debt/Equity of 2.14 and reported debt rising from $5.83B to $13.88B, with a Forensic Balance Sheet score of 10 of 20 and a P/E TTM of 33.3, leave limited margin for error.. FCF yield is 4.24% and RQD sits at 61/100 (C-) — why pay up here when you can wait for next quarter's numbers?